Médecins Sans Frontières/Doctors Without Borders (MSF) is urging the Australian government to back a landmark proposal that would make any COVID-19 drugs or vaccines more accessible, ahead of World Trade Organization (WTO) talks later this month.
A total of 99 countries have supported a proposal by India and South Africa to the WTO to waive certain intellectual property (IP) during the COVID-19 pandemic – but Australia is not one of these supporting countries.
“We are strongly urging the Australian government to put people over profits in this pandemic,” said Jennifer Tierney, MSF Australia’s Executive Director. “We’re calling on the Ministers for Trade and Health, Simon Birmingham and Greg Hunt, to get behind the proposal for a waiver that recognises the need for collective global action. This waiver is key to ensuring that all treatments, vaccines and diagnostics for COVID-19 are accessible and affordable, based on needs alone.”
The IP waiver would allow all countries to choose to neither grant nor enforce patents and other IP related to COVID-19 drugs, vaccines, diagnostics and other technologies for the duration of the pandemic, until global herd immunity is achieved. This move harkens back 20 years to the HIV/AIDS epidemic, when affordable generic HIV drugs, made in countries where patents did not block production, began saving millions of people’s lives.
“Not even a global pandemic can stop pharmaceutical corporations from following their business-as-usual approach, so countries need to use every tool available to make sure that COVID-19 medical products are accessible and affordable for everyone who needs them,” said Dr Sidney Wong, Executive Co-Director of MSF’s Access Campaign. “All COVID-19 health tools and technologies should be true global public goods, free from the barriers that patents and other intellectual property impose. We’re calling on all governments to urgently throw their support behind this groundbreaking proposal that puts human lives over corporate profits at this critical moment for global health.”
Since the start of the pandemic, pharmaceutical corporations have maintained their standard practice of rigid control over intellectual property rights, while pursuing secretive and monopolistic commercial deals that exclude many developing countries from benefitting. For example, Gilead entered into restrictive bilateral licensing for one of the only drugs to have shown potential benefit to treat COVID-19, remdesivir, excluding nearly half of the world’s population from benefitting from price-lowering generic competition.
Additionally, several new and repurposed medicines and monoclonal antibodies being trialed as promising treatments for COVID-19 are already patented in many developing countries such as Brazil, South Africa, India, Indonesia, China and Malaysia. And with the exception of one company, none of the COVID-19 vaccine developers have committed to treating IP any differently than the status quo. While some corporations have taken steps through licensing and technology transfer deals to use existing global manufacturing capacity to try and mitigate anticipated supply shortages of potentially successful vaccines, this has been the exception, and the licensing deals often come with clear limitations.
Historically, steps have been taken to overcome monopolies that have allowed pharmaceutical corporations to keep prices artificially high. In 2001, at the height of the HIV/AIDS epidemic, the ‘Doha Declaration on TRIPS and Public Health’ affirmed governments’ rights to take all necessary measures to eliminate patents and other IP barriers, putting governments in the driver’s seat so they can prioritise public health over corporate interests. This current waiver request to the WTO is a similar step to speed up the response to COVID-19.
“This bold step by governments offers the world a chance to avoid repeating the tragedy of the HIV/AIDS epidemic 20 years ago, when monopolies on lifesaving treatments saw people in high-income countries get access to HIV medicines while millions in developing countries were left to die,” said Dr Khosi Mavuso, Medical Representative for MSF in South Africa. “Overriding monopolies on COVID-19 medical tools will allow global collaboration to scale-up manufacturing, supply and access for everyone. With more than 1.3 million lives already lost to COVID-19, governments cannot afford to waste any more time waiting for voluntary moves by the pharmaceutical industry.”
At the last WTO meeting of the TRIPS Council (Trade-related Aspects of Intellectual Property Rights) on 15/16 October, Kenya and E-swatini joined India and South Africa in officially co-sponsoring the waiver. A total of 99 countries have welcomed and shown support overall. But the waiver proposal is not being supported by multiple wealthy nations, including the US, the UK, Japan, Canada, Brazil, Australia, Norway, Switzerland and the European Union.
“Governments need to ask themselves which side of history they want to be on when the books on this pandemic are written,” said Wong.
For more information about MSF's Access Campaign, please contact Maya Zahran, Media Coordinator, [email protected] or +61 431 567 020.
The Australian section of MSF was established in 1995 and is one of 24 international MSF offices around the world committed to delivering medical humanitarian assistance to populations in crisis. Last year up to 200 field positions were filled by Australians and New Zealanders. MSF delivers medical care based on need alone and operates independently of government, religion or economic influence and irrespective of race, religion or gender. For more information visit www.msf.org.au